Document resource
Background Triple negative breast cancer is the kind of breast cancer that does not have any receptors which are usually found in breast cancer. It is estrogen-receptor, progesterone-receptor, and HER-2 receptor negative. About 10-15% of all breast cancers are triple negative. Its commonly seen in women aged than 40 years, and those have a BRCA-1 mutation. This is a more aggressive form of cancer, harder to treat and has chances of recurrences. The single most prognostic factor is still the pathological complete response in case of neoadjuvant (NACT) settings.Methods This observational study is aimed to find out the Pathological Complete Response (pCR) at the time of definitive surgery who had received chemotherapy along with Pembrolizumab as neoadjuvant settings. After the definitive surgery the biopsy was observed and based on the reports the response was documented as pCR.Results Among the 6 patients the age range is 37-75 years and only 2 was right sided where the 4 is left sided breast primary. The stage was 50% (3) for stage III and 50% (3) were stage II. Histological Grade ranging of moderate differentiated mostly 4 case where 2 was G-III. All the 5-case had high Ki-67 and only 1 had low (8%). All these 6 cases received NACT settings with 3 weekly 8 cycles of Pembrolizumab 200mg with Weekly Paclitaxel + Carboplatin weekly for 12 weeks followed by 3 weekly Anthracycline + Cyclophosphamide for 4 cycles. After definitive surgery 2 by MRM whereas rest 4 had lumpectomy with Sentinal LN biopsy or axillary dissection. Post operative histopathology confirm the treatment response by complete pathological response pCR by 5 cases (83.33%) except 1 (16.67%)Conclusions pCR is the primary denominator for TNBC cases and it is around 50-70 percents of the study populations. In this small observational study, we also noticed the excellent outcome in regards of pCR by adding the Pembrolizumab efficacy. But further larger inclusions of cases and head-to-head comparative study can show some additional results and needs further study to see the pCR outcomes in Bangladeshi populations. This is the first documented data that is like higher in pCR in comparison to KEYNOTE 522.